胰腺癌常见突变基因在肿瘤微环境调节中的作用
The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
作者信息
Sun Hongzhi, Zhang Bo, Li Haijun
机构信息
Department of General Surgery, Shenzhen Luohu People's Hospital, The Third Affiliated Hospital of Shenzhen University, Shenzhen, China.
出版信息
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820920969. doi: 10.1177/1533033820920969.
Abstract
Pancreatic ductal adenocarcinoma has extremely high malignancy and patients with pancreatic ductal adenocarcinoma have dismal prognosis. The failure of pancreatic ductal adenocarcinoma treatment is largely due to the tumor microenvironment, which is featured by ample stromal cells and complicated extracellular matrix. Recent genomic analysis revealed that pancreatic ductal adenocarcinoma harbors frequently mutated genes including , , , and , which can widely alter cellular processes and behaviors. As shown by accumulating studies, these mutant genes may also change tumor microenvironment, which in turn affects pancreatic ductal adenocarcinoma progression. In this review, we summarize the role of such genetic mutations in tumor microenvironment regulation and potential mechanisms.
摘要
胰腺导管腺癌具有极高的恶性程度，胰腺导管腺癌患者的预后很差。胰腺导管腺癌治疗失败很大程度上归因于肿瘤微环境，其特征是有大量基质细胞和复杂的细胞外基质。最近的基因组分析显示，胰腺导管腺癌含有频繁突变的基因，包括 、 、 和 ，这些基因可广泛改变细胞过程和行为。越来越多的研究表明，这些突变基因也可能改变肿瘤微环境，进而影响胰腺导管腺癌的进展。在本综述中，我们总结了此类基因突变在肿瘤微环境调节中的作用及潜在机制。
相似文献
1
The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820920969. doi: 10.1177/1533033820920969.
2
Genetics and Biology of Pancreatic Ductal Adenocarcinoma.
Hematol Oncol Clin North Am. 2015 Aug;29(4):595-608. doi: 10.1016/j.hoc.2015.04.003. Epub 2015 Jun 10.
3
Clinical Effect of Driver Mutations of , and in Pancreatic Cancer: A Meta-Analysis.
Genet Test Mol Biomarkers. 2020 Dec;24(12):777-788. doi: 10.1089/gtmb.2020.0078.
4
The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification.
BMC Cancer. 2022 Feb 18;22(1):186. doi: 10.1186/s12885-022-09279-9.
5
Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
Cancer. 2020 Sep 1;126(17):3939-3949. doi: 10.1002/cncr.33038. Epub 2020 Jun 23.
6
Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Ann Surg. 2013 Aug;258(2):336-46. doi: 10.1097/SLA.0b013e3182827a65.
7
Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease.
J Natl Cancer Inst. 2024 Sep 1;116(9):1429-1438. doi: 10.1093/jnci/djae095.
8
Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Br J Surg. 2016 Aug;103(9):1189-99. doi: 10.1002/bjs.10187. Epub 2016 Jun 3.
9
Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
Pancreas. 2017 Mar;46(3):335-340. doi: 10.1097/MPA.0000000000000760.
10
[Will molecular diagnostics become established in pancreatic pathology?].
Pathologe. 2013 Nov;34 Suppl 2:214-20. doi: 10.1007/s00292-013-1865-z.
引用本文的文献
1
A novel defined manganese metabolism-related gene signature for predicting the prognosis of pancreatic ductal adenocarcinoma.
Oncol Lett. 2025 Jul 9;30(3):436. doi: 10.3892/ol.2025.15182. eCollection 2025 Sep.
2
Extracellular Signal-Regulated Kinase Inhibitor SCH772984 Augments the Anti-Cancer Effects of Gemcitabine in Nanoparticle Form in Pancreatic Cancer Models.
Int J Mol Cell Med. 2024;13(3):220-233. doi: 10.22088/IJMCM.BUMS.13.3.220.
3
Novel Methodology for the Design of Personalized Cancer Vaccine Targeting Neoantigens: Application to Pancreatic Ductal Adenocarcinoma.
Diseases. 2024 Jul 11;12(7):149. doi: 10.3390/diseases12070149.
4
Synergistic effect of additional anlotinib and immunotherapy as second-line or later-line treatment in pancreatic cancer: A retrospective cohort study.
Cancer Innov. 2024 May 14;3(4):e123. doi: 10.1002/cai2.123. eCollection 2024 Aug.
5
Unveiling the immunosuppressive landscape of pancreatic ductal adenocarcinoma: implications for innovative immunotherapy strategies.
Front Oncol. 2024 Mar 25;14:1349308. doi: 10.3389/fonc.2024.1349308. eCollection 2024.
6
Construction and validation of a RARRES3-based prognostic signature related to the specific immune microenvironment of pancreatic cancer.
Front Oncol. 2024 Feb 5;14:1246308. doi: 10.3389/fonc.2024.1246308. eCollection 2024.
7
Reshaping the Pancreatic Cancer Microenvironment at Different Stages with Chemotherapy.
Cancers (Basel). 2023 Apr 25;15(9):2448. doi: 10.3390/cancers15092448.
8
Cuproptosis-Related genes in the prognosis of colorectal cancer and their correlation with the tumor microenvironment.
Front Genet. 2022 Sep 28;13:984158. doi: 10.3389/fgene.2022.984158. eCollection 2022.
9
Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression.
Cells. 2022 Jul 9;11(14):2155. doi: 10.3390/cells11142155.
10
The Desmoplastic Stroma of Pancreatic Cancer: Multilayered Levels of Heterogeneity, Clinical Significance, and Therapeutic Opportunities.
Cancers (Basel). 2022 Jul 5;14(13):3293. doi: 10.3390/cancers14133293.
本文引用的文献
1
Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein.
Autophagy. 2020 Nov;16(11):2069-2083. doi: 10.1080/15548627.2020.1714209. Epub 2020 Jan 16.
2
ARF6 and AMAP1 are major targets of and mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer.
Proc Natl Acad Sci U S A. 2019 Aug 27;116(35):17450-17459. doi: 10.1073/pnas.1901765116. Epub 2019 Aug 9.
3
Immune-related somatic mutation genes are enriched in PDACs with diabetes.
Transl Oncol. 2019 Sep;12(9):1147-1154. doi: 10.1016/j.tranon.2019.03.006. Epub 2019 Jun 13.
4
KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.
Cancer Cell. 2019 Apr 15;35(4):559-572.e7. doi: 10.1016/j.ccell.2019.02.008. Epub 2019 Mar 21.
5
Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
Gastroenterology. 2019 Jun;156(8):2242-2253.e4. doi: 10.1053/j.gastro.2019.02.037. Epub 2019 Mar 2.
6
Kras mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer.
Cancer Lett. 2019 Apr 1;446:103-111. doi: 10.1016/j.canlet.2019.01.013. Epub 2019 Jan 18.
7
Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance.
Clin Cancer Res. 2018 Sep 15;24(18):4444-4454. doi: 10.1158/1078-0432.CCR-17-3401. Epub 2018 Apr 16.
8
KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment.
Cancer Res. 2018 Jan 1;78(1):7-14. doi: 10.1158/0008-5472.CAN-17-2084. Epub 2017 Dec 20.
9
PDAC-derived exosomes enrich the microenvironment in MDSCs in a -dependent manner through a new calcium related axis.
Oncotarget. 2017 Sep 13;8(49):84928-84944. doi: 10.18632/oncotarget.20863. eCollection 2017 Oct 17.
10
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.
Cancer Cell. 2017 Aug 14;32(2):185-203.e13. doi: 10.1016/j.ccell.2017.07.007.
Zotero 插件